Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503094
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-17
Brief Title:
CD19 CD20 Bispecific CAR T Cells for Relapsed Refractory B Cell Hematological Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Safety and Efficacy of CD19 CD20 Bispecific CAR T Cells in Treating Relapsed Refractory B Cell Hematological Tumors
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multi-center open prospective single-arm clinical study of patients with relapsed refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 CD20 bispecific CAR-T cells in relapsed refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells
Detailed Description:
Since 2010 CAR-T chimeric antigen receptor T cell therapy has shown good results in tumor treatment and has achieved positive clinical therapeutic effects in hematological tumors The structure of the dual-target CAR-T of CD19 CD20 is designed with a 4-1BB costimulatory domain and an antigenic recognition region with a tandem structural sequence to recognize CD20 or CD19 by a single structure CD19 CD20 bispecific CAR-T cells can identify CD 19 or CD 20 with the advantage that the single target CAR-T does not have reducing the possibility of target loss The structure has been optimized to enhance the safety to treat B cell-derived hematological tumors at least CD19 positive or CD20 positive
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None